Search

The article focuses on a large study of an experimental Alzheimer's drug, donanemab, which suggests that early treatment in the disease's mild stages offers a better chance of slowing cognitive decline.

The article focuses on a research finding that discovered a mutation in a specific gene that protected a man from developing Alzheimer's disease until a much later age. Topics include the potential for this finding to lead to new therapeutic approaches for Alzheimer's, the protein Reelin's role in preventing the formation of characteristic Alzheimer's structures, and the need for further research and combined treatments to explore this pathway.

The article discusses pharmaceutical Biogen Idec's development of the Alzheimer's drug aducanumab (BIIB037), highlighting research that found that the drug slowed the decline in mental function during a clinical trial. Topics addressed include stock market reaction to the research results, the drug's reduction of amyloid plaque in the brain, and comparison's to other Alzheimer's drugs.

The article focuses on the study led by Rebecca F. Gottesman which shows the five risk factors of developing amyloid brain plaques including obesity, high blood pressure, and diabetes.

The article reports on several studies which revealed that the presence of amyloid plaques in the brain can help identify who are at risk of Alzheimer's disease and determine who has it, highlighting the views of physician Samuel Gandy on the issue.